Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 228-232 , February 2010

Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design

  • Kenichi Shikata

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    • ,
  • Masakazu Haneda

      Affiliations

    • Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Asahikawa, Japan
    • ,
  • Daisuke Koya

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan
    • ,
  • Yoshiki Suzuki

      Affiliations

    • Health Administration Center, Niigata University, Niigata, Japan
    • ,
  • Yasuhiko Tomino

      Affiliations

    • Division of Nephrology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
    • ,
  • Kenichi Yamada

      Affiliations

    • Metabolic Diseases Clinic, Chiba, Japan
    • ,
  • Shiro Maeda

      Affiliations

    • Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic Medicine, Yokohama, Japan
    • ,
  • Norito Kawakami

      Affiliations

    • Department of Mental Health, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    • ,
  • Takashi Uzu

      Affiliations

    • Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan
    • ,
  • Motonobu Nishimura

      Affiliations

    • Department of Internal Medicine, Japan National Hospital Organization Chiba-East National Hospital, Chiba, Japan
    • ,
  • Chikage Sato

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    • ,
  • Daisuke Ogawa

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    • ,
  • Hirofumi Makino

      Affiliations

    • Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    • Corresponding Author InformationCorresponding author at: Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. Tel.: +81 86 235 7235; fax: +81 86 222 5214.
    • ,
  • DNETT-Japan Study Group

Received 7 August 2009 ,Accepted 28 September 2009.

References 

  1. Japanese Society for Dialysis Therapy . Condition as of December 31, 2007. An Overview of Regular Dialysis Treatment in Japan. Japanese Society for Dialysis Therapy; 2008;pp. 2–22 (in Japanese)
  2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  3. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol. 2003;14:3217–3232
  4. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617–622
  5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  6. Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes. 2005;54:2983–2987
  7. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 2009;53:982–992
  8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment, risk of complications in patients with type 2 diabetes, (UKPDS, 33). Lancet. 1998;352:837–853
  9. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545–2559
  10. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995;28:103–117
  11. American Diabetes Association . Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2002;25:85S–89S
  12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572
  13. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828
  14. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007;30:1577–1578
  15. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001;345:870–878
  16. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861–869
  17. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860
  18. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–1444
  19. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358:580–591

PII: S0168-8227(09)00417-3

doi: 10.1016/j.diabres.2009.09.025

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 228-232 , February 2010

Article Tools

* Image Usage & Resolution